We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Progress Toward Measles Elimination - African Region, 2013-2016.
- Authors
Masresha, Balcha G.; Dixon, Meredith G.; Kriss, Jennifer L.; Katsande, Reggis; Shibeshi, Messeret E.; Luce, Richard; Fall, Amadou; Dosseh, Annick R. G. A.; Byabamazima, Charles R.; Dabbagh, Alya J.; Goodson, James L.; Mihigo, Richard
- Abstract
In 2011, the 46 World Health Organization (WHO) African Region (AFR) member states established a goal of measles elimination* by 2020, by achieving 1) ≥95% coverage of their target populations with the first dose of measles-containing vaccine (MCV1) at national and district levels; 2) ≥95% coverage with measles-containing vaccine (MCV) per district during supplemental immunization activities (SIAs); and 3) confirmed measles incidence of <1 case per 1 million population in all countries (1). Two key surveillance performance indicator targets include 1) investigating ≥2 cases of nonmeasles febrile rash illness per 100,000 population annually, and 2) obtaining a blood specimen from ≥1 suspected measles case in ≥80% of districts annually (2). This report updates the previous report (3) and describes progress toward measles elimination in AFR during 2013-2016. Estimated regional MCV1 coverage† increased from 71% in 2013 to 74% in 2015.§ Seven (15%) countries achieved ≥95% MCV1 coverage in 2015.¶ The number of countries providing a routine second MCV dose (MCV2) increased from 11 (24%) in 2013 to 23 (49%) in 2015. Forty-one (79%) of 52 SIAs** during 2013-2016 reported ≥95% coverage. Both surveillance targets were met in 19 (40%) countries in 2016. Confirmed measles incidence in AFR decreased from 76.3 per 1 million population to 27.9 during 2013-2016. To eliminate measles by 2020, AFR countries and partners need to 1) achieve ≥95% 2-dose MCV coverage through improved immunization services, including second dose (MCV2) introduction; 2) improve SIA quality by preparing 12-15 months in advance, and using readiness, intra-SIA, and post-SIA assessment tools; 3) fully implement elimination-standard surveillance††; 4) conduct annual district-level risk assessments; and 5) establish national committees and a regional commission for the verification of measles elimination.
- Subjects
AFRICA; MEASLES prevention; VACCINATION; MEASLES vaccines; DISEASE incidence; PUBLIC health
- Publication
MMWR: Morbidity & Mortality Weekly Report, 2017, Vol 66, Issue 17, p436
- ISSN
0149-2195
- Publication type
journal article
- DOI
10.15585/mmwr.mm6617a2